Shares of Stryker Corporation cratered 10.6% to $278.68 on October 30, wiping out roughly $35 billion in market capitalization after the orthopedic and surgical equipment maker slashed its full-year outlook following a disappointing third quarter. For a company long considered one of the most reliable growers in medical devices, the miss raises pointed questions about whether its premium valuation was built on unsustainable expectations. Stryker's Worst Day in Years: Can the Medical Device Giant Recover From a Self-Inflicted Growth Reset?
Shares of Stryker plunged 10.6% to $278.68 after the medical device maker cut its 2026 outlook following a third quarter that CEO Kevin Lobo conceded "did fall short of our expectations." The company posted adjusted earnings of $3.52 per share, missing estimates by $0.03, while revenue of $6.52 billion fell $100 million short of projections. The selloff vaporized roughly $35 billion in market value from a company that investors had long treated as one of the steadiest compounders in healthcare.
The Growth Forecast Took a Dramatic Haircut. Stryker now expects full-year organic sales growth of 6.5%–7.0%, down sharply from its previous projection of 8.3%–9.3%.
It also cut adjusted EPS guidance to $14.80–$14.90 — a range entirely below the $14.95 consensus. That's not a fine-tuning; it's an admission that the second half of the year is fundamentally weaker than planned. Management blamed softer hip and knee procedure trends, lingering supply constraints in its peripheral vascular business, and execution risks tied to capital equipment sales.
Competitors May Be Eating Stryker's Lunch. Stryker blamed a slowing market for the orthopedic miss, but Johnson & Johnson grew hips and knees faster in the same quarter, pointing to company-specific execution issues.
A cybersecurity incident and an SAP system implementation also disrupted commercial execution.
Zimmer Biomet and Smith+Nephew report next week , which will reveal how much of the softness is Stryker's alone versus industry-wide.
Wall Street Hit the Price Targets Hard. Citigroup slashed its target from $360 to $315 , RBC Capital cut from $420 to $375 , and Needham dropped from $418 to $359.
Sixteen analysts still rate the stock a Buy versus eight Holds, with an average target of $355.84 — implying about 28% upside, but confidence is clearly shaken.
The Silver Lining Is Razor-Thin. Adjusted operating income rose 10.1% and margins expanded 60 basis points to 26.2%, reflecting improved cost discipline.
Stryker also repurchased $1 billion of its own stock during the quarter. But margin gains alone won't sustain a premium stock price if the top line keeps decelerating. With hip-and-knee demand pressured by affordability concerns and rising insurance premiums , the question now is whether Stryker can reignite growth — or whether the market is finally repricing a stock that had been valued for perfection.